GlassScriptPhysician profile
Kaleem Aslam
NPI 1578727509
$9,018.64
in general payments reported to CMS, 2019-2025
36 companies · $1,809 in 2025
The $1,809 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,274 · 2020: $36.17 · 2021: $696 · 2022: $1,452 · 2023: $1,959 · 2024: $1,794 · 2025: $1,809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,148 · Education: $413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,148.19 |
| Education | $413.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,502.74 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $1,453.74 | 2019-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $740.60 | 2021-2025 | |
| Horizon Therapeutics Plc | $695.64 | 2021-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $639.02 | 2019-2025 | Rayaldee |
| Amgen INC. | $559.10 | 2024-2025 | Krystexxa, Tavneos |
| Mallinckrodt Hospital Products INC. | $382.37 | 2021-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $305.07 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $286.95 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $279.20 | 2019-2025 | Filspari |
| Daiichi Sankyo INC. | $212.18 | 2021-2025 | Injectafer |
| Ardelyx, INC. | $184.28 | 2024-2025 | Ibsrela |
| Nxstage Medical, INC. | $174.17 | 2023-2025 | Liberty Select Cycler, Nxstage System One |
| Alexion Pharmaceuticals, INC. | $166.95 | 2022-2024 | Ultomiris |
| Glaxosmithkline, LLC. | $162.63 | 2021-2025 | Benlysta, Jesduvroq |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $128.35 | 2019-2025 | Vafseo |
| Mallinckrodt Enterprises LLC | $123.88 | 2019 | |
| Novo Nordisk INC | $115.32 | 2024-2025 | Ozempic, Rivfloza, Rybelsus |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $106.01 | 2022-2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $102.18 | 2021-2024 | Lupkynis |
| Fresenius USA Marketing, INC. | $101.84 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.90 | 2023-2025 | Jardiance |
| Renalytix Ai, INC. | $74.34 | 2023-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Ultragenyx Pharmaceutical INC. | $60.85 | 2021-2023 | |
| Ani Pharmaceuticals, INC. | $55.07 | 2022-2024 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $54.39 | 2021-2023 | Livtencity |
| Abbvie INC. | $49.36 | 2021 | |
| Lilly USA, LLC | $35.44 | 2024-2025 | Jardiance |
| Vifor Pharma, INC. | $33.99 | 2022-2023 | Veltassa |
| Baxter Healthcare | $31.36 | 2019 | |
| Shield Therapeutics INC | $25.38 | 2025 | |
| Boston Scientific Corporation | $24.60 | 2024 | |
| Abiomed | $19.69 | 2023 | Impella |
| Edwards Lifesciences Corporation | $19.13 | 2021 | |
| Azurity Pharmaceuticals, INC. | $18.38 | 2025 | Horizant |
| Cormedix INC. | $17.54 | 2024 | Defencath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaleem Aslam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.